Homemade beauty treatments equal healthy skin without the chemicals. Hence it is important to prepare these homemade skin care treatments with utmost hygiene. Lack of hygiene practiced while preparing these products will defeat the purpose of the beautiful skin care treatment you are treating yourself to. Here are five crucial things to remember before making and using homemade beauty products.
*Data Courtesy:? Hanson Mingus is a guest blogger and aesthetician. Hanson is currently starting a blog to help people create safe, inexpensive homemade acne products.
A noninvasive avenue for Parkinson's disease gene therapyPublic release date: 21-Apr-2013 [ | E-mail | Share ]
Contact: Jim Bernstein jbernstein@aspet.org 301-646-3259 Federation of American Societies for Experimental Biology
BOSTON Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain. Parkinson's is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the substantia nigra (SN). Loss of these neurons leads to the characteristic tremor and slowed movements of PD, which get increasingly worse with time. Currently, more than 1% of the population over age 60 has PD and approximately 60,000 Americans are newly diagnosed every year. The available drugs on the market for PD mimic or replace the lost dopamine but do not get to the heart of the problem, which is the progressive loss of the dopamine neurons.
The focus of Dr. Barbara Waszczak's lab at Northeastern University in Boston is to find a way to harvest the potential of glial cell line-derived neurotrophic factor (GDNF) as a treatment for PD. GDNF is a protein known to nourish dopamine neurons by activating survival and growth-promoting pathways inside the cells. Not surprisingly, GDNF is able to protect dopamine neurons from injury and restore the function of damaged and dying neurons in many animal models of PD. However, the action of GDNF is limited by its inability to cross the blood-brain barrier (BBB), thus requiring direct surgical injection into the brain. To circumvent this problem, Waszczak's lab is investigating intranasal delivery as a way to bypass the BBB. Their previous work showed that intranasal delivery of GDNF protects dopamine neurons from damage by the neurotoxin, 6-hydroxydopamine (6-OHDA), a standard rat model of PD.
Taking this work a step further, Brendan Harmon, working in Waszczak's lab, has adapted the intranasal approach so that cells in the brain can continuously produce GDNF. His work utilized nanoparticles, developed by Copernicus Therapeutics, Inc., which are able to transfect brain cells with an expression plasmid carrying the gene for GDNF (pGDNF). When given intranasally to rats, these pGDNF nanoparticles increase GDNF production throughout the brain for long periods, avoiding the need for frequent re-dosing. Now, in new research presented on April 20 at 12:30 pm during Experimental Biology 2013 in Boston, MA, Harmon reports that intranasal administration of Copernicus' pGDNF nanoparticles results in GDNF expression sufficient to protect SN dopamine neurons in the 6-OHDA model of PD.
Waszczak and Harmon believe that intranasal delivery of Copernicus' nanoparticles may provide an effective and non-invasive means of GDNF gene therapy for PD, and an avenue for transporting other gene therapy vectors to the brain. This work, which was funded in part by the Michael J. Fox Foundation for Parkinson's Research and Northeastern University, has the potential to greatly expand treatment options for PD and many other central nervous system disorders.
###
To request an interview with Dr. Waszczak, please contact Jim Bernstein at the contact information listed above.
About Experimental Biology 2013
Experimental Biology's mission is to share the newest scientific concepts and research findings shaping future and current clinical advances and to give scientists and clinicians an unparalleled opportunity to hear from colleagues working on similar biomedical problems using different disciplines. With six sponsoring societies and another 20 U.S. and international guest societies, the annual meeting brings together scientists from throughout the United States and the world, representing dozens of scientific areas, from laboratory to translational to clinical research. The meeting also offers a wide spectrum of professional development sessions.
About the American Society for Pharmacology and Experimental Therapeutics
ASPET is a 5,100 member scientific society whose members conduct basic and clinical pharmacological research within the academic, industrial and government sectors. Our members discover and develop new medicines and therapeutic agents that fight existing and emerging diseases, as well as increase our knowledge regarding how therapeutics affects humans.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
A noninvasive avenue for Parkinson's disease gene therapyPublic release date: 21-Apr-2013 [ | E-mail | Share ]
Contact: Jim Bernstein jbernstein@aspet.org 301-646-3259 Federation of American Societies for Experimental Biology
BOSTON Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain. Parkinson's is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the substantia nigra (SN). Loss of these neurons leads to the characteristic tremor and slowed movements of PD, which get increasingly worse with time. Currently, more than 1% of the population over age 60 has PD and approximately 60,000 Americans are newly diagnosed every year. The available drugs on the market for PD mimic or replace the lost dopamine but do not get to the heart of the problem, which is the progressive loss of the dopamine neurons.
The focus of Dr. Barbara Waszczak's lab at Northeastern University in Boston is to find a way to harvest the potential of glial cell line-derived neurotrophic factor (GDNF) as a treatment for PD. GDNF is a protein known to nourish dopamine neurons by activating survival and growth-promoting pathways inside the cells. Not surprisingly, GDNF is able to protect dopamine neurons from injury and restore the function of damaged and dying neurons in many animal models of PD. However, the action of GDNF is limited by its inability to cross the blood-brain barrier (BBB), thus requiring direct surgical injection into the brain. To circumvent this problem, Waszczak's lab is investigating intranasal delivery as a way to bypass the BBB. Their previous work showed that intranasal delivery of GDNF protects dopamine neurons from damage by the neurotoxin, 6-hydroxydopamine (6-OHDA), a standard rat model of PD.
Taking this work a step further, Brendan Harmon, working in Waszczak's lab, has adapted the intranasal approach so that cells in the brain can continuously produce GDNF. His work utilized nanoparticles, developed by Copernicus Therapeutics, Inc., which are able to transfect brain cells with an expression plasmid carrying the gene for GDNF (pGDNF). When given intranasally to rats, these pGDNF nanoparticles increase GDNF production throughout the brain for long periods, avoiding the need for frequent re-dosing. Now, in new research presented on April 20 at 12:30 pm during Experimental Biology 2013 in Boston, MA, Harmon reports that intranasal administration of Copernicus' pGDNF nanoparticles results in GDNF expression sufficient to protect SN dopamine neurons in the 6-OHDA model of PD.
Waszczak and Harmon believe that intranasal delivery of Copernicus' nanoparticles may provide an effective and non-invasive means of GDNF gene therapy for PD, and an avenue for transporting other gene therapy vectors to the brain. This work, which was funded in part by the Michael J. Fox Foundation for Parkinson's Research and Northeastern University, has the potential to greatly expand treatment options for PD and many other central nervous system disorders.
###
To request an interview with Dr. Waszczak, please contact Jim Bernstein at the contact information listed above.
About Experimental Biology 2013
Experimental Biology's mission is to share the newest scientific concepts and research findings shaping future and current clinical advances and to give scientists and clinicians an unparalleled opportunity to hear from colleagues working on similar biomedical problems using different disciplines. With six sponsoring societies and another 20 U.S. and international guest societies, the annual meeting brings together scientists from throughout the United States and the world, representing dozens of scientific areas, from laboratory to translational to clinical research. The meeting also offers a wide spectrum of professional development sessions.
About the American Society for Pharmacology and Experimental Therapeutics
ASPET is a 5,100 member scientific society whose members conduct basic and clinical pharmacological research within the academic, industrial and government sectors. Our members discover and develop new medicines and therapeutic agents that fight existing and emerging diseases, as well as increase our knowledge regarding how therapeutics affects humans.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
18 April 2013Last updated at 19:17 ETBy Helen BriggsBBC News
Dinosaur fossils unearthed in Madagascar are of a new species that roamed the Earth about 90 million years ago, say US researchers.
The remains date back to a time when India and Madagascar were one landmass cut off from the rest of the world.
Revealing the discovery in the journal PLOS ONE, scientists say the dinosaur was a bi-pedal meat-eater about the size of a large cow.
It has been named Dahalokely tokana, which means "lonely small bandit".
Madagascar is a treasure trove for palaeontologists, yielding thousands of well-preserved fossils.
Continue reading the main story
?Start Quote
This just reinforces the importance of exploring new areas around the world where undiscovered dinosaur species are still waiting?
End QuoteJoe SertichDenver Museum of Nature and Science
But the latest discovery is the first new dinosaur species unearthed on the island in almost a decade.
Its Malagasy name refers to its carnivorous diet and isolation on a landmass in the middle of the ocean.
The discovery fills a gap in the fossil record and raises intriguing questions about the evolution of animals on both Madagascar and India, which separated at about the time this newly identified creature walked the Earth.
Andrew Farke of the Raymond M Alf Museum of Paleontology in Claremont, California, says it belongs to a group called the Abelisauridae, which were common to the southern continents.
He told BBC News: "The most intriguing thing for me is that it fills a major gap in what we know about the history of dinosaurs in Madagascar.
"It shortens it by about 20 million years. It would have been a meat-eater, walking on two legs about the size of a large cow, with a tail."
Joe Sertich, curator of dinosaurs at the Denver Museum of Nature and Science, who discovered the dinosaur, said it was closely related to well-known dinosaurs from southern continents.
"This just reinforces the importance of exploring new areas around the world where undiscovered dinosaur species are still waiting."
Apr. 18, 2013 ? Up to 10 per cent of the population are affected by specific learning disabilities (SLDs), such as dyslexia, dyscalculia and autism, translating to 2 or 3 pupils in every classroom, according to a new article.
The review -- by academics at UCL and Goldsmiths -- also indicates that children are frequently affected by more than one learning disability.
The research, published today in Science, helps to clarify the underlying causes of learning disabilities and the best way to tailor individual teaching and learning for affected individuals and education professionals.
Specific learning disabilities arise from atypical brain development with complicated genetic and environmental causes, causing such conditions as dyslexia, dyscalculia, attention-deficit/hyperactivity disorder, autism spectrum disorder and specific language impairment.
While these conditions in isolation already provide a challenge for educators, an additional problem is that specific learning disabilities also co-occur for more often that would be expected. As, for example, in children with attention-deficit/hyperactivity disorder, 33 to 45 per cent also suffer from dyslexia and 11 per cent from dyscalculia.
Lead author Professor Brian Butterworth (UCL Institute of Cognitive Neuroscience) said: "We now know that there are many disorders of neurological development that can give rise to learning disabilities, even in children of normal or even high intelligence, and that crucially these disabilities can also co-occur far more often that you'd expect based on their prevalence.
"We are also finally beginning to find effective ways to help learners with one or more SLDs, and although the majority of learners can usually adapt to the one-size-fits-all approach of whole class teaching, those with SLDs will need specialised support tailored to their unique combination of disabilities."
As part of the study, Professor Butterworth and Dr Yulia Kovas (Goldsmiths) have summarised what is currently known about SLD's neural and genetic basis to help clarify what is causing these disabilities to develop, helping to improve teaching for individual learners, and also training for school psychologists, clinicians and teachers.
What the team hope is that by developing an understanding of how individual differences in brain development interact with formal education, and also adapting learning pathways to individual needs, those with specific learning disabilities will produce more tailored education for such learners.
Professor Butterworth said: "Each child has a unique cognitive and genetic profile, and the educational system should be able to monitor and adapt to the learner's current repertoire of skills and knowledge.
"A promising approach involves the development of technology-enhanced learning applications -- such as games -- that are capable of adapting to individual needs for each of the basic disciplines."
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University College London, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
B. Butterworth, Y. Kovas. Understanding Neurocognitive Developmental Disorders Can Improve Education for All. Science, 2013; 340 (6130): 300 DOI: 10.1126/science.1231022
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Apr. 18, 2013 ? The first new species of dinosaur from Madagascar in nearly a decade was announced today, filling an important gap in the island's fossil record.
Dahalokely tokana (pronounced "dah-HAH-loo-KAY-lee too-KAH-nah") is estimated to have been between nine and 14 feet long, and it lived around 90 million years ago. Dahalokely belongs to a group called abelisauroids, carnivorous dinosaurs common to the southern continents. Up to this point, no dinosaur remains from between 165 and 70 million years ago could be identified to the species level in Madagascar-a 95 million year gap in the fossil record. Dahalokely shortens this gap by 20 million years.
The fossils of Dahalokely were excavated in 2007 and 2010, near the city of Antsiranana (Diego-Suarez) in northernmost Madagascar. Bones recovered included vertebrae and ribs. Because this area of the skeleton is so distinct in some dinosaurs, the research team was able to definitively identify the specimen as a new species. Several unique features -- including the shape of some cavities on the side of the vertebrae -- were unlike those in any other dinosaur. Other features in the vertebrae identified Dahalokely as an abelisauroid dinosaur.
When Dahalokely was alive, Madagascar was connected to India, and the two landmasses were isolated in the middle of the Indian Ocean. Geological evidence indicates that India and Madagascar separated around 88 million years ago, just after Dahalokely lived. Thus, Dahalokely potentially could have been ancestral to animals that lived later in both Madagascar and India. However, not quite enough of Dahalokely is yet known to resolve this issue. The bones known so far preserve an intriguing mix of features found in dinosaurs from both Madagascar and India.
"We had always suspected that abelisauroids were in Madagascar 90 million years ago, because they were also found in younger rocks on the island. Dahalokely nicely confirms this hypothesis," said project leader Andrew Farke, Augustyn Family Curator of Paleontology at the Raymond M. Alf Museum of Paleontology. Farke continued, "But, the fossils of Dahalokely are tantalizingly incomplete -- there is so much more we want to know. Was Dahalokely closely related to later abelisauroids on Madagascar, or did it die out without descendents?"
The name "Dahalokely tokana" is from the Malagasy language, meaning "lonely small bandit." This refers to the presumed carnivorous diet of the animal, as well as to the fact that it lived at a time when the landmasses of India and Madagascar together were isolated from the rest of the world.
"This dinosaur was closely related to other famous dinosaurs from the southern continents, like the horned Carnotaurus from Argentina and Majungasaurus, also from Madagascar," said project member Joe Sertich, Curator of Dinosaurs at the Denver Museum of Nature & Science and the team member who discovered the new dinosaur. "This just reinforces the importance of exploring new areas around the world where undiscovered dinosaur species are still waiting," added Sertich.
The research was funded by the Jurassic Foundation, Sigma Xi, National Science Foundation, and the Raymond M. Alf Museum of Paleontology. The paper naming Dahalokely appears in the April 18, 2013, release of the journal PLOS ONE.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Raymond M. Alf Museum of Paleontology.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
Andrew A. Farke, Joseph J. W. Sertich. An Abelisauroid Theropod Dinosaur from the Turonian of Madagascar. PLoS ONE, 2013; 8 (4): e62047 DOI: 10.1371/journal.pone.0062047
Note: If no author is given, the source is cited instead.
Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.
Apr 15 (Reuters) - Leading money winners on the 2013 PGATour on Monday (U.S. unless stated): 1. Tiger Woods $4,139,600 2. Brandt Snedeker $3,137,920 3. Matt Kuchar $2,442,389 4. Adam Scott (Australia) $2,100,469 5. Steve Stricker $1,935,340 6. Phil Mickelson $1,764,680 7. Dustin Johnson $1,748,907 8. Jason Day $1,659,565 9. Hunter Mahan $1,553,965 10. Keegan Bradley $1,430,347 11. Charles Howell III $1,393,806 12. John Merrick $1,375,757 13. Russell Henley $1,331,434 14. Michael Thompson $1,310,709 15. Kevin Streelman $1,310,343 16. Bill Haas $1,271,553 17. Billy Horschel $1,254,224 18. ...
'); document.getElementById('commentBoxRes').style.display="block"; }else{ $("#commentBoxRes").show(); $.post("http://healthmeup.com/tpl/tplGetcommentadded.php",{"content_id":content_id,"pageval":"1"},function(data){ //alert(data); $("#showcommentcontent").html(data); $("#commentBoxRes").html('
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_tTSkET48UABOxc9N6Xw8adu0FkDAz_v6MR5MSvDMD8NUCStzPc1-_-K82ccj_k0ChdwGjhExAdAD44z9L3-uG_af59ZUu2-MElPBEQdLQ=s0-d){kind=small}
Public release date: 21-Apr-2013
Share ]